Cargando…

Epigenomic signature of major congenital heart defects in newborns with Down syndrome

BACKGROUND: Congenital heart defects (CHDs) affect approximately half of individuals with Down syndrome (DS) but the molecular reasons for incomplete penetrance are unknown. Previous studies have largely focused on identifying genetic risk factors associated with CHDs in individuals with DS, but com...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouat, Julia S., Li, Shaobo, Myint, Swe Swe, Laufer, Benjamin I., Lupo, Philip J., Schraw, Jeremy M., Woodhouse, John P., de Smith, Adam J., LaSalle, Janine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187438/
https://www.ncbi.nlm.nih.gov/pubmed/37205408
http://dx.doi.org/10.1101/2023.05.02.23289417
_version_ 1785042738130976768
author Mouat, Julia S.
Li, Shaobo
Myint, Swe Swe
Laufer, Benjamin I.
Lupo, Philip J.
Schraw, Jeremy M.
Woodhouse, John P.
de Smith, Adam J.
LaSalle, Janine M.
author_facet Mouat, Julia S.
Li, Shaobo
Myint, Swe Swe
Laufer, Benjamin I.
Lupo, Philip J.
Schraw, Jeremy M.
Woodhouse, John P.
de Smith, Adam J.
LaSalle, Janine M.
author_sort Mouat, Julia S.
collection PubMed
description BACKGROUND: Congenital heart defects (CHDs) affect approximately half of individuals with Down syndrome (DS) but the molecular reasons for incomplete penetrance are unknown. Previous studies have largely focused on identifying genetic risk factors associated with CHDs in individuals with DS, but comprehensive studies of the contribution of epigenetic marks are lacking. We aimed to identify and characterize DNA methylation differences from newborn dried blood spots (NDBS) of DS individuals with major CHDs compared to DS individuals without CHDs. METHODS: We used the Illumina EPIC array and whole-genome bisulfite sequencing (WGBS) to quantitate DNA methylation for 86 NDBS samples from the California Biobank Program: 1) 45 DS-CHD (27 female, 18 male) and 2) 41 DS non-CHD (27 female, 14 male). We analyzed global CpG methylation and identified differentially methylated regions (DMRs) in DS-CHD vs DS non-CHD comparisons (both sex-combined and sex-stratified) corrected for sex, age of blood collection, and cell type proportions. CHD DMRs were analyzed for enrichment in CpG and genic contexts, chromatin states, and histone modifications by genomic coordinates and for gene ontology enrichment by gene mapping. DMRs were also tested in a replication dataset and compared to methylation levels in DS vs typical development (TD) WGBS NDBS samples. RESULTS: We found global CpG hypomethylation in DS-CHD males compared to DS non-CHD males, which was attributable to elevated levels of nucleated red blood cells and not seen in females. At a regional level, we identified 58, 341, and 3,938 CHD-associated DMRs in the Sex Combined, Females Only, and Males Only groups, respectively, and used machine learning algorithms to select 19 Males Only loci that could distinguish CHD from non-CHD. DMRs in all comparisons were enriched for gene exons, CpG islands, and bivalent chromatin and mapped to genes enriched for terms related to cardiac and immune functions. Lastly, a greater percentage of CHD-associated DMRs than background regions were differentially methylated in DS vs TD samples. CONCLUSIONS: A sex-specific signature of DNA methylation was detected in NDBS of DS-CHD compared to DS non-CHD individuals. This supports the hypothesis that epigenetics can reflect the variability of phenotypes in DS, particularly CHDs.
format Online
Article
Text
id pubmed-10187438
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-101874382023-05-17 Epigenomic signature of major congenital heart defects in newborns with Down syndrome Mouat, Julia S. Li, Shaobo Myint, Swe Swe Laufer, Benjamin I. Lupo, Philip J. Schraw, Jeremy M. Woodhouse, John P. de Smith, Adam J. LaSalle, Janine M. medRxiv Article BACKGROUND: Congenital heart defects (CHDs) affect approximately half of individuals with Down syndrome (DS) but the molecular reasons for incomplete penetrance are unknown. Previous studies have largely focused on identifying genetic risk factors associated with CHDs in individuals with DS, but comprehensive studies of the contribution of epigenetic marks are lacking. We aimed to identify and characterize DNA methylation differences from newborn dried blood spots (NDBS) of DS individuals with major CHDs compared to DS individuals without CHDs. METHODS: We used the Illumina EPIC array and whole-genome bisulfite sequencing (WGBS) to quantitate DNA methylation for 86 NDBS samples from the California Biobank Program: 1) 45 DS-CHD (27 female, 18 male) and 2) 41 DS non-CHD (27 female, 14 male). We analyzed global CpG methylation and identified differentially methylated regions (DMRs) in DS-CHD vs DS non-CHD comparisons (both sex-combined and sex-stratified) corrected for sex, age of blood collection, and cell type proportions. CHD DMRs were analyzed for enrichment in CpG and genic contexts, chromatin states, and histone modifications by genomic coordinates and for gene ontology enrichment by gene mapping. DMRs were also tested in a replication dataset and compared to methylation levels in DS vs typical development (TD) WGBS NDBS samples. RESULTS: We found global CpG hypomethylation in DS-CHD males compared to DS non-CHD males, which was attributable to elevated levels of nucleated red blood cells and not seen in females. At a regional level, we identified 58, 341, and 3,938 CHD-associated DMRs in the Sex Combined, Females Only, and Males Only groups, respectively, and used machine learning algorithms to select 19 Males Only loci that could distinguish CHD from non-CHD. DMRs in all comparisons were enriched for gene exons, CpG islands, and bivalent chromatin and mapped to genes enriched for terms related to cardiac and immune functions. Lastly, a greater percentage of CHD-associated DMRs than background regions were differentially methylated in DS vs TD samples. CONCLUSIONS: A sex-specific signature of DNA methylation was detected in NDBS of DS-CHD compared to DS non-CHD individuals. This supports the hypothesis that epigenetics can reflect the variability of phenotypes in DS, particularly CHDs. Cold Spring Harbor Laboratory 2023-05-05 /pmc/articles/PMC10187438/ /pubmed/37205408 http://dx.doi.org/10.1101/2023.05.02.23289417 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Mouat, Julia S.
Li, Shaobo
Myint, Swe Swe
Laufer, Benjamin I.
Lupo, Philip J.
Schraw, Jeremy M.
Woodhouse, John P.
de Smith, Adam J.
LaSalle, Janine M.
Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title_full Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title_fullStr Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title_full_unstemmed Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title_short Epigenomic signature of major congenital heart defects in newborns with Down syndrome
title_sort epigenomic signature of major congenital heart defects in newborns with down syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187438/
https://www.ncbi.nlm.nih.gov/pubmed/37205408
http://dx.doi.org/10.1101/2023.05.02.23289417
work_keys_str_mv AT mouatjulias epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT lishaobo epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT myintsweswe epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT lauferbenjamini epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT lupophilipj epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT schrawjeremym epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT woodhousejohnp epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT desmithadamj epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome
AT lasallejaninem epigenomicsignatureofmajorcongenitalheartdefectsinnewbornswithdownsyndrome